Cas 1227093-50-6,1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea

1227093-50-6

Post Buying Request

Basic information

Product Name: 1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea
Synonyms: 1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea
CAS NO:1227093-50-6
Molecular Formula:
Molecular Weight: 395.356
EINECS: N/A
Product Categories: N/A
Mol File: 1227093-50-6.mol
Article Data: 1

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea(CAS DataBase Reference)
NIST Chemistry Reference: 1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea(1227093-50-6)
EPA Substance Registry System: 1-(3,4-dichlorobenzyl)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)thiourea(1227093-50-6)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1227093-50-6(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1227093-50-6 Suppliers

Recommended suppliersmore

1227093-50-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1227093-50-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,0,9 and 3 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1227093-50:
(9*1)+(8*2)+(7*2)+(6*7)+(5*0)+(4*9)+(3*3)+(2*5)+(1*0)=136
136 % 10 = 6
So 1227093-50-6 is a valid CAS Registry Number.

1227093-50-6Upstream product

1227093-50-6Downstream Products

1227093-50-6Relevant articles and documents

COMPOUNDS USEFUL AS HIV BLOCKERS

-

Page/Page column 87-88, (2010/06/15)

The present invention relates to a compound having the general Formula (I): wherein the variables are as defined in the specification. The present invention further relates to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular for the treatment or prevention of chemokine-mediated disorders such as HIV infection.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1227093-50-6